Hybridon is a leader in the development of oligonucleotide chemistries for therapeutics and diagnostics. These platforms allow Hybridon to create value through a combination of in-house development of products, collaborations with partners and the licensing of broadly applicable technology. Inc. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and financing such activities. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements.
Copies are available from the respective companies.
GeneTrove and Ibis Therapeutics are trademarks of Isis Pharmaceuticals, Inc.